We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$269M
AUM Growth
+$2.58M
Cap. Flow
-$7.75M
Cap. Flow %
-2.88%
Top 10 Hldgs %
61.2%
Holding
83
New
15
Increased
18
Reduced
11
Closed
33

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$9.5M
2
ASMB icon
Assembly Biosciences
ASMB
+$8.21M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$5.14M
4
IRIX icon
IRIDEX
IRIX
+$4.74M
5
ASND icon
Ascendis Pharma A/S
ASND
+$4.24M

Top Sells

Rank Stock Value
1
EVDY
Everyday Health, Inc.
EVDY
+$11.9M
2
AERI
Aerie Pharmaceuticals
AERI
+$8.7M
3
CEMP
Cempra, Inc.
CEMP
+$5.08M
4
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$3.9M
5
FOLD
Amicus Therapeutics
FOLD
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 77.17%
2 Technology 2.58%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
1
Veracyte
VCYT
$3.58B
$27.2M 10.11%
3,513,161
+368,512
+12% +$2.76M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.93B
$26.5M 9.85%
3,809,944
+580,028
+18% +$3.99M
IRIX icon
3
IRIDEX
IRIX
$14.4M
$21.9M 8.13%
1,554,146
+333,535
+27% +$4.74M
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$17.2M 6.41%
4,700,000
+850,000
+22% +$2.51M
NDRM
5
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$14.8M 5.5%
665,944
+202,988
+44% +$3.8M
PDSB icon
6
PDS Biotechnology
PDSB
$40M
$13M 4.84%
52,013
+16,863
+48% +$3.83M
ASMB icon
7
Assembly Biosciences
ASMB
$503M
$11.9M 4.41%
81,383
+55,199
+211% +$8.21M
ASND icon
8
Ascendis Pharma A/S
ASND
$16B
$11.6M 4.33%
575,309
+212,309
+58% +$4.24M
ACRS icon
9
Aclaris Therapeutics
ACRS
$772M
$10.1M 3.76%
+372,753
New +$9.5M
IWM icon
10
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$9.44M 3.51%
70,000
+30,000
+75% +$3.83M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.39B
$8.65M 3.22%
300,000
+80,000
+36% +$2.12M
CEMI
12
DELISTED
Chembio diagnostics, Inc.
CEMI
$7.83M 2.91%
1,150,925
+379,249
+49% +$2.63M
AKBA icon
13
Akebia Therapeutics
AKBA
$351M
$7.28M 2.71%
698,825
-1,175
-0.2% -$10.1K
OXFD
14
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.04M 2.62%
470,834
+63,019
+15% +$885K
MRVL icon
15
Marvell Technology
MRVL
$174B
$6.93M 2.58%
500,000
-10,000
-2% -$136K
CASM
16
DELISTED
CAS Medical Systems, Inc.
CASM
$6.73M 2.5%
4,179,838
+334,473
+9% +$562K
RARX
17
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$5.74M 2.13%
+377,909
New +$5.14M
GWPH
18
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.47M 1.66%
40,000
-1,487
-4% -$179K
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.21M 1.57%
2,826
+492
+21% +$653K
WBMD
20
DELISTED
WebMD Health Corp.
WBMD
$3.97M 1.47%
80,000
-15,000
-16% -$775K
DBVT
21
DBV Technologies
DBVT
$804M
$3.23M 1.2%
9,190
+3,564
+63% +$1.28M
VCYT icon
22
CALL
Veracyte
VCYT
$3.58B
$2.9M 1.08%
+375,000
New +$2.8M
DERM
23
DELISTED
Dermira, Inc.
DERM
$2.68M 1%
88,500
-18,500
-17% -$596K
VNDA icon
24
Vanda Pharmaceuticals
VNDA
$315M
$2.59M 0.96%
162,600
-83,395
-34% -$1.34M
SCTL
25
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2.42M 0.9%
+334,500
New +$2.29M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Acuta Capital Partners held 83 positions worth $269M, up 0.97% from $266M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Acuta Capital Partners's Q4 2016 filing shows 15 new, 18 increased, 11 reduced and 33 closed positions. Its largest new stake was Aclaris Therapeutics: 372,753 shares worth $10.1M. The largest sale was Everyday Health, Inc., an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.

  • Acuta Capital Partners's largest Q4 2016 buy was Aclaris Therapeutics: 372,753 shares worth $10.1M.
  • Acuta Capital Partners added most to Assembly Biosciences in Q4 2016, an estimated $8.21M increase.
  • Acuta Capital Partners's biggest Q4 2016 reduction was Aerie Pharmaceuticals, cutting an estimated $8.7M.
  • Acuta Capital Partners fully exited Everyday Health, Inc. in Q4 2016, selling an estimated $11.9M.
  • Acuta Capital Partners's ten largest holdings make up 61% of its $269M portfolio in Q4 2016.
  • Acuta Capital Partners opened 15 new positions and closed 33 in Q4 2016.
  • Acuta Capital Partners's portfolio value rose 0.97% quarter-over-quarter to $269M.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.